新的抗癫痫药物对现有第二代抗癫痫药物。
文章的细节
-
引用
复制到剪贴板 -
比亚尔米
新的抗癫痫药物对现有第二代抗癫痫药物。
专家当今Investig药物。2006年6月,15 (6):637 - 47。
- PubMed ID
-
16732716 (在PubMed]
- 文摘
-
在过去的十年中,10引入了新的抗癫痫药物(aed)提供明显的优势的有利的药物动力学,提高耐受性,降低潜在的药物相互作用。然而,尽管治疗大范围的新旧aed,大约30%的患者癫痫症还没有自由,因此,大量需要开发新的aed。当前发展的新aed可分为两类:药物与全新化学结构如lacosamide(正式harkoseride) retigabine, rufinamide talampanel;和现有aed的药物衍生物或类似物,可视为第二代或后续建立aed的化合物。本文主要关注第二类,因此批判性评论下面的第二代化合物:eslicarbazepine醋酸或bia - 2 - 093和10-hydroxy carbazepine(卡马西平衍生品);valrocemide NPS 1776 (isovaleramide;丙戊酸衍生品);普瑞巴林和XP13512(加巴喷丁衍生品);34714年brivaracetam (ucb)和seletracetam (ucb 44212;levetiracetam衍生品); and fluorofelbamate (a felbamate derivative). In addition, a series of valproic acid derivatives that are currently in preclinical stage has also been evaluated because some lead compounds of this series have a promising potential to become new antiepileptics and CNS drugs. For any of these follow-up compounds to become a successful second generation to an existing AED, it has to be more potent, safer and possess favourable pharmacokinetics, including low potential for pharmacokinetic and pharmacodynamic drug interactions.
DrugBank数据引用了这篇文章
- 药物